suspected or confirmed as fever(axillary temperature ≥37.3°c / oral temperature ≥37.5°c) within 72 hours before the enrollment, or axillary temperature ≥37.3°c / oral temperature ≥37.5°c at the day of screening; diastolic blood pressure ≥ 100mmhg and / or systolic blood pressure ≥ 150mmhg; patients with previous history of a covid-19; detection of sars-cov-2 nucleic acid or antibody is positive; those who are suffering from the following diseases: with thrombocytopenia, any coagulation dysfunction or receiving anti-coagulatory treatment congenital or acquired immune deficiency or autoimmune disease history; no spleen, or history of splenic surgery and trauma, or receiving immunomodulator treatment within 6 months, e.g., immunosuppressive dose of glucocorticoids (reference dose: equivalent to 20mg/ day of prednisone, over 1 week); or monoclonal antibodies; or thymosin; or interferon etc.; however, topical application (such as ointment, eye drops, inhalers or nasal sprays) is permitted; symptoms related to acute respiratory tract infection (such as sneezing, nasal congestion, runny nose, cough, sore throat, loss of taste, chills, shortness of breath, etc.); cancer patients (except basal cell carcinoma). with a history of serious allergy to any vaccine or any composition of investigational product (including: aluminum preparations), such as allergic shock, allergic throat edema, allergic purpura, thrombocytopenic purpura, localized allergic necrosis reaction (arthus reaction), dyspnea and angioneuroedema; inoculated with subunit vaccine and inactivated vaccine within 14 days before the first dosing of investigational vaccine, or inoculated with attenuated live vaccine within 30 days; previous receiving blood transfusion or blood relevant products (including immunoglobulin) within 3 months, or planning to receive such products from the starting of study to <6 months after the whole-course inoculation; have participated in or are participating in other covid-19 related clinical trials; women in breastfeeding period or in pregnant period (including women at childbearing age with positive result of urine pregnancy test); considered by investigators as any disease or state possibly making the subject at unacceptable risk; not conforming to the requirements of study protocol; interference of assessment of reactions of vaccine.

suspected or confirmed as fever(axillary temperature ≥37.3°c / oral temperature ≥37.5°c) within 72 hours before the enrollment, or axillary temperature ≥37.3°c / oral temperature ≥37.5°c at the day of screening; diastolic blood pressure ≥ 100mmhg and / or systolic blood pressure ≥ 150mmhg; patients with previous history of a covid-19; detection of sars-cov-2 nucleic acid or antibody is positive; those who are suffering from the following diseases: with thrombocytopenia, any coagulation dysfunction or receiving anti-coagulatory treatment congenital or acquired immune deficiency or autoimmune disease history; no spleen, or history of splenic surgery and trauma, or receiving immunomodulator treatment within 6 months, e.g., immunosuppressive dose of glucocorticoids (reference dose: equivalent to 20mg/ day of prednisone, over 1 week); or monoclonal antibodies; or thymosin; or interferon etc.; however, topical application (such as ointment, eye drops, inhalers or nasal sprays) is permitted; symptoms related to acute respiratory tract infection (such as sneezing, nasal congestion, runny nose, cough, sore throat, loss of taste, chills, shortness of breath, etc.); cancer patients (except basal cell carcinoma). with a history of serious allergy to any vaccine or any composition of investigational product (including: aluminum preparations), such as allergic shock, allergic throat edema, allergic purpura, thrombocytopenic purpura, localized allergic necrosis reaction (arthus reaction), dyspnea and angioneuroedema; inoculated with subunit vaccine and inactivated vaccine within 14 days before the first dosing of investigational vaccine, or inoculated with attenuated live vaccine within 30 days; previous receiving blood transfusion or blood relevant products (including immunoglobulin) within 3 months, or planning to receive such products from the starting of study to <6 months after the whole-course inoculation; have participated in or are participating in other covid-19 related clinical trials; women in breastfeeding period or in pregnant period (including women at childbearing age with positive result of urine pregnancy test); considered by investigators as any disease or state possibly making the subject at unacceptable risk; not conforming to the requirements of study protocol; interference of assessment of reactions of vaccine.

- suspected or confirmed as fever(axillary temperature ≥37.3°c / oral temperature ≥37.5°c) within 72 hours before the enrollment, or axillary temperature ≥37.3°c / oral temperature ≥37.5°c at the day of screening; - diastolic blood pressure ≥ 100mmhg and / or systolic blood pressure ≥ 150mmhg; - patients with previous history of a covid-19; - detection of sars-cov-2 nucleic acid or antibody is positive; - those who are suffering from the following diseases: 1. with thrombocytopenia, any coagulation dysfunction or receiving anti-coagulatory treatment 2. congenital or acquired immune deficiency or autoimmune disease history; no spleen, or history of splenic surgery and trauma, or receiving immunomodulator treatment within 6 months, e.g., immunosuppressive dose of glucocorticoids (reference dose: equivalent to 20mg/ day of prednisone, over 1 week); or monoclonal antibodies; or thymosin; or interferon etc.; however, topical application (such as ointment, eye drops, inhalers or nasal sprays) is permitted; 3. symptoms related to acute respiratory tract infection (such as sneezing, nasal congestion, runny nose, cough, sore throat, loss of taste, chills, shortness of breath, etc.); 4. cancer patients (except basal cell carcinoma). - with a history of serious allergy to any vaccine or any composition of investigational product (including: aluminum preparations), such as allergic shock, allergic throat edema, allergic purpura, thrombocytopenic purpura, localized allergic necrosis reaction (arthus reaction), dyspnea and angioneuroedema; - inoculated with subunit vaccine and inactivated vaccine within 14 days before the first dosing of investigational vaccine, or inoculated with attenuated live vaccine within 30 days; - previous receiving blood transfusion or blood relevant products (including immunoglobulin) within 3 months, or planning to receive such products from the starting of study to <6 months after the whole-course inoculation; - have participated in or are participating in other covid-19 related clinical trials; - women in breastfeeding period or in pregnant period (including women at childbearing age with positive result of urine pregnancy test); - considered by investigators as any disease or state possibly making the subject at unacceptable risk; not conforming to the requirements of study protocol; interference of assessment of reactions of vaccine.

- suspected or confirmed as fever(axillary temperature ≥37.3°c / oral temperature ≥37.5°c) within 72 hours before the enrollment, or axillary temperature ≥37.3°c / oral temperature ≥37.5°c at the day of screening; - diastolic blood pressure ≥ 100mmhg and / or systolic blood pressure ≥ 150mmhg; - patients with previous history of a covid-19; - detection of sars-cov-2 nucleic acid or antibody is positive; - those who are suffering from the following diseases: 1. with thrombocytopenia, any coagulation dysfunction or receiving anti-coagulatory treatment 2. congenital or acquired immune deficiency or autoimmune disease history; no spleen, or history of splenic surgery and trauma, or receiving immunomodulator treatment within 6 months, e.g., immunosuppressive dose of glucocorticoids (reference dose: equivalent to 20mg/ day of prednisone, over 1 week); or monoclonal antibodies; or thymosin; or interferon etc.; however, topical application (such as ointment, eye drops, inhalers or nasal sprays) is permitted; 3. symptoms related to acute respiratory tract infection (such as sneezing, nasal congestion, runny nose, cough, sore throat, loss of taste, chills, shortness of breath, etc.); 4. cancer patients (except basal cell carcinoma). - with a history of serious allergy to any vaccine or any composition of investigational product (including: aluminum preparations), such as allergic shock, allergic throat edema, allergic purpura, thrombocytopenic purpura, localized allergic necrosis reaction (arthus reaction), dyspnea and angioneuroedema; - inoculated with subunit vaccine and inactivated vaccine within 14 days before the first dosing of investigational vaccine, or inoculated with attenuated live vaccine within 30 days; - previous receiving blood transfusion or blood relevant products (including immunoglobulin) within 3 months, or planning to receive such products from the starting of study to <6 months after the whole-course inoculation; - have participated in or are participating in other covid-19 related clinical trials; - women in breastfeeding period or in pregnant period (including women at childbearing age with positive result of urine pregnancy test); - considered by investigators as any disease or state possibly making the subject at unacceptable risk; not conforming to the requirements of study protocol; interference of assessment of reactions of vaccine.